[Expression and Clinical Significance of N-cadherin in Bone Marrow Leukemic Cells Derived from Patients with Acute Leukemia]

Jie Ma; Ya-Jie Liu; Qiu-Tang Zhang; Qing-Feng Yu; Zhan-Fang Zhang; Meng-Ying Zhang; Chong Wang; Si-Lin Gan; Sheng-Mei Chen; Wei-Jie Cao; Xin-Sheng Xie; Liu Yan-Fang; Lin-Xiang Liu; Ding-Ming Wan; Fang Wang; Ling Sun; Hui Sun

doi:10.7534/j.issn.1009-2137.2016.05.005

[Expression and Clinical Significance of N-cadherin in Bone Marrow Leukemic Cells Derived from Patients with Acute Leukemia]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Oct;24(5):1312-1318. doi: 10.7534/j.issn.1009-2137.2016.05.005.

[Article in Chinese]

Authors

Jie Ma¹, Ya-Jie Liu², Qiu-Tang Zhang², Qing-Feng Yu², Zhan-Fang Zhang², Meng-Ying Zhang², Chong Wang², Si-Lin Gan², Sheng-Mei Chen², Wei-Jie Cao², Xin-Sheng Xie², Liu Yan-Fang², Lin-Xiang Liu², Ding-Ming Wan², Fang Wang², Ling Sun², Hui Sun²

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail: majie318@163.com.cn.
² Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.

PMID: 27784348
DOI: 10.7534/j.issn.1009-2137.2016.05.005

Abstract

Objective: To investigate the expression of N-cadherin in bone marrow leukemic cells derived from acute leukemia patients and its clinical significances.

Methods: A total of 113 patients with acute leukemia were enrolled in this study. Flow cytometry was employed to detect the expression of N-Cadherin in bone marrow leukemic cells from acute leukemia patients and the relationships between the N-cadherin expression and the clinical characteristics of patients with acute leukemia were analyzed.

Results: The expression of N-Cadherin in bone marrow leukemic cells deriveted from patients with acute leukemia was variable with 0%-99.7%. For adult AML patients, the positive rate of CD34 in N-cadherin⁺ group was significantly higher than that in N-cadherin^- group(67.39% vs 33.33%)(P=0.013), while the differences of total CR rate and rate of CR after 1 cycle of induction treatment were not significant between these 2 groups(P>0.05). As to ALL patients, N-cadherin⁺ group had significant lower WBC count (21.31±7.07 vs 51.10±23.69)(P=0.008) and lower percentage of peripheral blood blast (43.22±5.75% vs 66.45±5.65%)(P=0.015). The CR rate after 1 cycle of induction treatment and rate of overall CR were lower and the relapse rate was higher in N-cadherin⁺ ALL group than those in N-cadherin^- ALL group, but the differences were not significant (P>0.05). For childhood ALL, the positive rate of CD33 in N-cadherin⁺ group was significantly higher than that in N-cadherin^- group(47.62% vs 0%)(P=0.012). The relapse rate was higher in N-cadherin⁺ group than that in N-cadherin^- group (30.00% vs 0%)(P=0.115). The median survival time, 3-year overall OS rate and 3-year relapse-free survival rate in N-cadherin^- groups of adult AML, non-M3 AML, ALL and chidhood ALL paients were superior to N-cadherin⁺ groups, but the differences were not significant.

Conclusion: The expression of N-cadherin in bone marrow leukemic cells relates to some clinical features of patients with acute leukemia and to some extent has inferior effect on survival of patients with acute leukemia.

MeSH terms

Acute Disease
Bone Marrow Cells
Bone Marrow*
Cadherins
Flow Cytometry
Hematologic Tests
Humans
Leukemia, Myeloid, Acute
Prognosis
Recurrence
Survival Rate

Substances

Cadherins